Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Liver biopsies show persistent FVIII after gene therapy for hemophilia A

Publish date:: July 16, 2020

Key clinical point: Factor VIII expression was detected on liver biopsies at more than 2 years after a single infusion of AAV gene therapy for hemophilia A.

Major finding: A dose-dependent increase was seen in the percentage of hepatocytes that stained positive for vector genomes (1.3% in the lower dose and 32% in the higher dose patients).

Study details: A liver biopsy substudy of a phase 1/2 study, with results from the first two patients.

Disclosures: Dr. Fong is an employee of BioMarin Pharmaceuticals.

Citation:

Fong S et al. 2020 ISTH Congress, Abstract OC 03.2.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Bleeding Disorders

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

Hemochromatosis variants may confer 10-fold higher risk of liver cancer,

Hemophilia, von Willebrand disease do not increase postop complications for ACL reconstruction,

Mouth splints decrease risk of post–dental extraction bleeding in hemophilia,

Low VWF levels or blood group O not linked to intracerebral hemorrhage risk,